Suppr超能文献

两种瓜尔胶制剂对糖尿病患者糖化血红蛋白、总胆固醇和甘油三酯的影响。

Influence of two guar preparations on glycosylated hemoglobin, total cholesterol and triglycerides in patients with diabetes mellitus.

作者信息

Kirsten R, Heintz B, Nelson K, Oremek G, Speck U

机构信息

Department of Clinical Pharmacology, University of Frankfurt, Germany.

出版信息

Int J Clin Pharmacol Ther Toxicol. 1992 Dec;30(12):582-6.

PMID:1335441
Abstract

Guar smoothens postprandial glucose peaks and reduces serum cholesterol. Both properties are advantageous for diabetic patients and can be realized, in part, by adding fiber to the diet. Depending on the blood glucose concentration, a small portion is incorporated into hemoglobin (HbA1), building a largely irreversible complex, making it a long-term indicator of blood glucose status. HbA1 may increase from a normal value of about 5% to as much as 20% of total hemoglobin in diabetics. This study tested the efficacy of two guar preparations in diabetic patients over 3 months by measuring HbA1, cholesterol and triglycerides. Forty diabetic patients with HbA1 > 10% ingested either 3 x 4 g daily of a new guar preparation (GU-052, Steigerwald, Darmstadt, Germany) or 3 x 5 g daily of Glucotard (Boehringer, Mannheim, Germany) for 12 weeks. Before and after 30, 60 and 90 days of treatment, HbA1, cholesterol and triglycerides were determined. After 90 days of treatment, GU-052 caused a reduction in HbA1 from 12.6 +/- 2.6% to 10.5 +/- 1.5% (-15.6 +/- 9.0%) in the GU-052 group and from 12.0 +/- 2.6% to 10.9 +/- 1.82% (-8.6 +/- 7.2%) in the Glucotard group. Cholesterol was reduced from 269 +/- 28 mg/100 ml on day 0 to 227 +/- 18 mg/100 ml on day 90 in the GU-052 group and from 261 +/- 40 to 235 +/- 26 mg/100 ml in the Glucotard group. Both GU-052 and Glucotard had little effect on plasma triglycerides. Fewer unpleasant side effects were reported for the GU-052 preparation than for Glucotard.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

瓜尔豆胶可使餐后血糖峰值趋于平稳,并降低血清胆固醇。这两种特性对糖尿病患者都有益,部分可通过在饮食中添加纤维来实现。根据血糖浓度,一小部分会结合到血红蛋白(HbA1)中,形成一种基本不可逆的复合物,使其成为血糖状态的长期指标。在糖尿病患者中,HbA1可能从正常的约5%增加到总血红蛋白的20%之多。本研究通过测量HbA1、胆固醇和甘油三酯,对两种瓜尔豆胶制剂在糖尿病患者中进行了为期3个月的疗效测试。40名HbA1>10%的糖尿病患者,连续12周每天服用3次,每次4克新的瓜尔豆胶制剂(GU - 052,德国达姆施塔特的施泰格瓦尔德公司)或每天服用3次,每次5克Glucotard(德国曼海姆的勃林格公司)。在治疗30、60和90天前后,测定HbA1、胆固醇和甘油三酯。治疗90天后,GU - 052组的HbA1从12.6±2.6%降至10.5±1.5%(-15.6±9.0%),Glucotard组从12.0±2.6%降至10.9±1.82%(-8.6±7.2%)。GU - 052组的胆固醇从第0天的269±28毫克/100毫升降至第90天的227±18毫克/100毫升,Glucotard组从261±40降至235±26毫克/100毫升。GU - 052和Glucotard对血浆甘油三酯的影响都很小。与Glucotard相比,GU - 052制剂报告的不良副作用更少。(摘要截断于250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验